-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
It took more than two months from the initial description of SARS-CoV-2 to its discovery of widespread spread in the United States.
despite the long intervals, PCR-specific quantitative reverse transcription (qRT) SARS-CoV-2 testing has been slow and has not been widely tested in the United States.
macro genome sequencing offers hope for non-biased detection of emerging pathogens without prior knowledge of the identity of the pathogen or its genome sequence.
to evaluate the macrogenome approach in the context of the current SARS-CoV-2 epidemic, laboratory-confirmed positive and negative samples from Seattle, Washington, were evaluated through macrogenome sequencing and compared with the 2019 Reference Genome Database created prior to the sars-CoV-2.
in laboratory-validated SARS-CoV-2 cases, we clearly identified a new human betacoronavirus within 36 hours, closely related to the known bat Betacoronavirus.
samples also showed overinfection or progenitor of human paravirus 3 or Moras, highlighting the need to test SARS-CoV-2 directly rather than using a viral respiratory system to rule out infection.
RT-PCR-negative samples for SARS-CoV-2 were also negative for macrogenomic analysis, and the rhinovirus a and C were positive.
, unlike the target SARS-CoV-2 qRT-PCR test, macrogenomic analysis of these SARS-CoV-2 negative samples identified the candidate cause of respiratory symptoms in patients.
these results demonstrate the value of macrogenomic analysis in monitoring and responding to this and future viral pandemics.
.